• CEO Dr Nina Webster to present at Bioshares Biotech Summit in Queenstown, NZ
• Focus on company diversification strategy and key attributes of DMX-652
• DMX-200 in Phase 3 trial for FSGS and DMX-652 in Phase 2 trial for AKI

Dimerix Ltd, a clinical-stage biopharmaceutical company focused on kidney disease treatments, announced that CEO Dr Nina Webster will present at the 20th Bioshares Biotech Summit in Queenstown, New Zealand. The presentation will focus on Dimerix's diversification strategy, including geographical expansion and product portfolio, as well as the key attributes of its new asset DMX-652. DMX-200, Dimerix's lead program, is in Phase 3 clinical development for focal segmental glomerulosclerosis (FSGS), while DMX-652, a USP30 inhibitor, is in Phase 2 for acute kidney injury (AKI). The company has commercial partners in multiple territories, with potential milestone payments and royalties exceeding $1.9 billion.

Potential milestone payments and royalties exceeding $1.9 billion

The company is focused on achieving key value inflection points, including clinical trial milestones and potential additional licensing partners.